Peter E. Zage

2.4k total citations
64 papers, 1.7k citations indexed

About

Peter E. Zage is a scholar working on Neurology, Molecular Biology and Cancer Research. According to data from OpenAlex, Peter E. Zage has authored 64 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Neurology, 41 papers in Molecular Biology and 20 papers in Cancer Research. Recurrent topics in Peter E. Zage's work include Neuroblastoma Research and Treatments (50 papers), Cancer, Hypoxia, and Metabolism (20 papers) and Cancer therapeutics and mechanisms (17 papers). Peter E. Zage is often cited by papers focused on Neuroblastoma Research and Treatments (50 papers), Cancer, Hypoxia, and Metabolism (20 papers) and Cancer therapeutics and mechanisms (17 papers). Peter E. Zage collaborates with scholars based in United States, Canada and Spain. Peter E. Zage's co-authors include Sarah Burkhead Whittle, Valeria Smith, Sibo Zhao, Erin Doherty, Susan L. Cohn, Patrick A. Zweidler‐McKay, Linna Zhang, Sarah E. Woodfield, Helen R. Salwen and Alexandre Chlenski and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer.

In The Last Decade

Peter E. Zage

61 papers receiving 1.7k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Peter E. Zage 1.0k 837 460 348 165 64 1.7k
Jonathan A. Fletcher 1.2k 1.2× 423 0.5× 327 0.7× 517 1.5× 60 0.4× 12 2.0k
Barbara Banelli 1.2k 1.1× 213 0.3× 611 1.3× 441 1.3× 205 1.2× 58 1.8k
Rolf Christofferson 658 0.6× 276 0.3× 346 0.8× 239 0.7× 42 0.3× 33 1.0k
Mark Rosenblum 474 0.5× 757 0.9× 160 0.3× 285 0.8× 387 2.3× 17 1.8k
Nives Pećina‐Šlaus 810 0.8× 118 0.1× 261 0.6× 298 0.9× 111 0.7× 56 1.4k
Nicolas Skuli 1.6k 1.6× 203 0.2× 1.3k 2.8× 444 1.3× 232 1.4× 45 2.6k
Hakim Bouterfa 573 0.6× 709 0.8× 228 0.5× 1.0k 3.0× 123 0.7× 40 2.4k
Caroline Wigerup 525 0.5× 171 0.2× 584 1.3× 218 0.6× 45 0.3× 16 999
Esther Bridges 1.1k 1.1× 95 0.1× 744 1.6× 430 1.2× 72 0.4× 38 1.7k
Ida Rapa 828 0.8× 329 0.4× 788 1.7× 1.1k 3.1× 145 0.9× 66 2.5k

Countries citing papers authored by Peter E. Zage

Since Specialization
Citations

This map shows the geographic impact of Peter E. Zage's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter E. Zage with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter E. Zage more than expected).

Fields of papers citing papers by Peter E. Zage

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter E. Zage. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter E. Zage. The network helps show where Peter E. Zage may publish in the future.

Co-authorship network of co-authors of Peter E. Zage

This figure shows the co-authorship network connecting the top 25 collaborators of Peter E. Zage. A scholar is included among the top collaborators of Peter E. Zage based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter E. Zage. Peter E. Zage is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kim, William, et al.. (2023). Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy. Biochemical Pharmacology. 216. 115751–115751. 5 indexed citations
2.
Oesterheld, Javier, William S. Ferguson, Jacqueline M. Kraveka, et al.. (2023). Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score–Matched Survival Outcome Comparisons. Journal of Clinical Oncology. 42(1). 90–102. 28 indexed citations
3.
Eslin, Don, Peter E. Zage, Genevieve Bergendahl, et al.. (2023). A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma. International Journal of Cancer. 153(5). 1026–1034. 5 indexed citations
4.
Clorennec, Christophe Le, et al.. (2023). USP7 Inhibition Suppresses Neuroblastoma Growth via Induction of p53-Mediated Apoptosis and EZH2 and N-Myc Downregulation. International Journal of Molecular Sciences. 24(18). 13780–13780. 8 indexed citations
5.
Whittle, Sarah Burkhead, Valeria Smith, Allison Silverstein, et al.. (2020). Is high‐risk neuroblastoma induction chemotherapy possible without G‐CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors. Pediatric Blood & Cancer. 67(10). e28417–e28417. 3 indexed citations
6.
Flynn, Sean, Jing Zhang, Karen Messer, et al.. (2020). Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways. British Journal of Cancer. 123(4). 568–579. 33 indexed citations
7.
Whittle, Sarah Burkhead, Kalyani R. Patel, Linna Zhang, et al.. (2016). The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma. Investigational New Drugs. 34(6). 685–692. 20 indexed citations
8.
Whittle, Sarah Burkhead, Sahily Reyes‐Esteves, Monica Gireud, et al.. (2016). A Polymorphism in the FGFR4 Gene Is Associated With Risk of Neuroblastoma and Altered Receptor Degradation. Journal of Pediatric Hematology/Oncology. 38(2). 131–138. 12 indexed citations
9.
Stricker, Thomas, Andrés Morales La Madrid, Alexandre Chlenski, et al.. (2014). Validation of a prognostic multi‐gene signature in high‐risk neuroblastoma using the high throughput digital NanoString nCounter™ system. Molecular Oncology. 8(3). 669–678. 28 indexed citations
10.
Brown, Brandon, et al.. (2014). Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies. Cancer Biology & Therapy. 15(7). 851–861. 34 indexed citations
11.
Louis, Chrystal U., et al.. (2013). Congenital Neuroblastoma in a Neonate With Isotretinoin Embryopathy. Journal of Pediatric Hematology/Oncology. 36(2). e75–e77. 3 indexed citations
12.
Singh, A. L., Monica Gireud, Stephen A. Fletcher, et al.. (2011). Retinoic acid induces REST degradation and neuronal differentiation by modulating the expression of SCFβ‐TRCP in neuroblastoma cells. Cancer. 117(22). 5189–5202. 47 indexed citations
13.
Zage, Peter E., Riitta Nolo, Wendy Fang, et al.. (2011). Notch pathway activation induces neuroblastoma tumor cell growth arrest. Pediatric Blood & Cancer. 58(5). 682–689. 41 indexed citations
14.
Zage, Peter E., Shana L. Palla, Wendy Fang, et al.. (2010). A novel therapeutic combination for neuroblastoma. Cancer. 116(10). 2465–2475. 24 indexed citations
15.
Zweidler‐McKay, Patrick A., et al.. (2010). Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo. Cancer. 116(13). 3233–3243. 40 indexed citations
16.
Thress, Kenneth S., Terry Macintyre, Haiyun Wang, et al.. (2009). Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway. Molecular Cancer Therapeutics. 8(7). 1818–1827. 51 indexed citations
17.
Zage, Peter E., Morris Kletzel, Kevin Murray, et al.. (2008). Outcomes of the POG 9340/9341/9342 trials for children with high‐risk neuroblastoma: A report from the Children's Oncology Group. Pediatric Blood & Cancer. 51(6). 747–753. 66 indexed citations
18.
Zage, Peter E., Aaron J. Reitman, R. Seshadri, et al.. (2007). Outcomes of a two‐drug chemotherapy regimen for intraocular retinoblastoma. Pediatric Blood & Cancer. 50(3). 567–572. 22 indexed citations
19.
Liu, Shuqing, Yufeng Tian, Alexandre Chlenski, et al.. (2005). Cross-Talk between Schwann Cells and Neuroblasts Influences the Biology of Neuroblastoma Xenografts. American Journal Of Pathology. 166(3). 891–900. 34 indexed citations
20.
Zage, Peter E. & Eugene E. Marcantonio. (1998). The Membrane Proximal Region of the Integrin β Cytoplasmic Domain Can Mediate Oligomerization. Cell adhesion and communications/Cell adhesion and communication/Cell adhesion & communication. 5(5). 335–347. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonathan A. Fletcher Breakdown of academic impact, for papers by Barbara Banelli Breakdown of academic impact, for papers by Rolf Christofferson Breakdown of academic impact, for papers by Mark Rosenblum Breakdown of academic impact, for papers by Nives Pećina‐Šlaus Breakdown of academic impact, for papers by Nicolas Skuli Breakdown of academic impact, for papers by Hakim Bouterfa Breakdown of academic impact, for papers by Caroline Wigerup Breakdown of academic impact, for papers by Esther Bridges Breakdown of academic impact, for papers by Ida Rapa
Rankless by CCL
2026